Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 313
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | ||
| NCT01765855 | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects | ||
| NCT03418389 | Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia | ||
| NCT03124368 | A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN | ||
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | ||
| NCT01192425 | Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes | ||
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | ||
| NCT05314231 | Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria | ||
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | ||
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | ||
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT02128269 | Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome | ||
| NCT00744042 | Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ||
| NCT07160608 | Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT05288829 | A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants | ||
| NCT03310021 | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | ||
| NCT01716728 | Identification of Undiagnosed Lysosomal Acid Lipase Deficiency | ||
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | ||
| NCT01203826 | Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) | ||
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | ||
| NCT04958135 | Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants | ||
| NCT03181633 | A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype | ||
| NCT06967480 | Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | ||
| NCT02193867 | Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency | ||
| NCT06183931 | Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | ||
| NCT05303324 | Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults | ||
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT05981092 | A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) | ||
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | ||
| NCT05288660 | A Study of a Single Dose of ALXN1210 in Healthy Participants | ||
| NCT06160414 | A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT01522183 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry | ||
| NCT01849562 | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants | ||
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | ||
| NCT06015750 | Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia | ||
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants | ||
| NCT02496689 | Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT04889690 | Study of Multiple Doses of Danicopan in Healthy Participants | ||
| NCT05047523 | Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | ||
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants |
